Evidence map›Paper›PMID 29700775›Full record

ArticleMolecular neurobiology2019

Somatostatin Maintains Permeability and Integrity of Blood-Brain Barrier in β-Amyloid Induced Toxicity.

Seungil Paik, Rishi K Somvanshi, Ujendra Kumar

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Seungil PaikFaculty of Pharmaceutical Sciences, The University of British Columbia, V6T1Z3, Vancouver, BC, Canada.
Rishi K SomvanshiFaculty of Pharmaceutical Sciences, The University of British Columbia, V6T1Z3, Vancouver, BC, Canada.
Ujendra KumarFaculty of Pharmaceutical Sciences, The University of British Columbia, V6T1Z3, Vancouver, BC, Canada. Ujendra.kumar@ubc.ca.ORCID http://orcid.org/0000-0003-3619-1198

Funding

Canadian Institutes of Health Research GSD-134858Canadian Institutes of Health Research MOP 74465Natural Sciences and Engineering Research Council of Canada 16-05171Natural Sciences and Engineering Research Council of Canada 402594-11
6 · The paper itself

Abstract

In Alzheimer's disease (AD), the impaired clearance of β-amyloid peptide (Aβ) due to disrupted tight junction and transporter proteins is the prominent cause of disease progression. Somatostatin (SST) blocks the aggregation of Aβ and inflammation whereas reduction of SST levels in the CSF and brain tissue is associated with impaired cognitive function and memory loss. However, the role of SST in preservation of blood-brain barrier (BBB) integrity and functionality in Aβ-induced toxicity is not known. In the present study using human CMEC/D3 cells, we demonstrate that SST prevents Aβ-induced BBB permeability by regulating LRP1 and RAGE expression and improving the disrupted tight junction proteins. Furthermore, SST abrogates Aβ-induced JNK phosphorylation and expression of MMP2. Taken together, results presented here suggest that SST might serve as a therapeutic intervention in AD via targeting multiple pathways responsible for neurotoxicity, impaired BBB function, and disease progression.

Indexed as

Amyloid beta-PeptidesBlood-Brain BarrierCells, CulturedCytokinesHumansInterleukin-1betaJNK Mitogen-Activated Protein KinasesLow Density Lipoprotein Receptor-Related Protein-1Matrix Metalloproteinase 2Neuroprotective AgentsPermeabilityPhosphorylationReceptor for Advanced Glycation End ProductsSomatostatinTight Junction ProteinsTime FactorsAmyloid beta-PeptidesCytokinesInterleukin-1betaJNK Mitogen-Activated Protein KinasesLow Density Lipoprotein Receptor-Related Protein-1LRP1 protein, humanMatrix Metalloproteinase 2Neuroprotective AgentsReceptor for Advanced Glycation End ProductsSomatostatinTight Junction ProteinsAlzheimer’s diseaseBlood-brain barrierSomatostatinTight junction proteins and transporters

Identifiers

PMID29700775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.